Table 2Summary of McIlwaine 2014

StudyLimitationsApplicabilityOther commentsInc. costsInc. effectsInc. cost-effectivenessUncertainty
McIlwaine 2014Seriousa,b,cPartiallyd,e
  • Medical costs include the number of hospital days, antibiotic treatment and number of days on home IV
  • Resource use is based on the number of exacerbations
Total medical cost/participant (including equipment cost) over 1 year:
  • PEP $2,845
  • HFCWO $20,419
  • PEP 130 exacerbations
  • HFCWO 369 exacerbations
NRNot assessed

HFCWO, high frequency chest wall oscillation; NR, not reported; PEP, positive expiratory pressure

(a)

Absence of detail regarding: cost build up for HFCWO equipment, specific sources of cost data, definition of an exacerbation, perspective and study dates

(b)

Data in the paper is based on single values, there is no measure of data dispersion

(c)

The cost of HFCWO equipment has not been annuitised over the equipment lifespan which over estimates the cost of the vest over one year

(d)

Conference paper with limited details to assess with certainty

(e)

QALY not used as an outcome measure

From: Appendix K, Health Economics

Cover of Cystic Fibrosis
Cystic Fibrosis: Diagnosis and management.
NICE Guideline, No. 78.
National Guideline Alliance (UK).
Copyright © NICE 2017.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.